Topical bioequivalence advisory committee
Executive Summary
FDA's Office of Generic Drugs will present an update on its research into topical bioequivalence to the Pharmaceutical Science Advisory Committee at April 14 meeting. Discussion will focus on developing a decision tree that would classify topical products based on their site of action and the degree of formulation similarity. [Editor's Note: To 1watch a webcast of this meeting, go to 2www.FDAAdvisoryCommittee.com]. During the April 13-14, meeting, the committee will also discuss highly variable drugs, inhalation products and process analytical technologies (3"The Pink Sheet" March 22, 2004, In Brief)...
You may also be interested in...
Bioequivalence testing
Strategy for bioequivalence testing of highly variable drug products will be discussed by FDA's Pharmaceutical Science Advisory Committee on April 14. On April 13, the committee will discuss a proposal for resolving issues related to the parametric tolerance interval test for dose content uniformity for inhalation products. The committee will also receive updates from the Clinical Pharmacology Subcommittee and on the progress of FDA's process analytical technologies effort. [To 1watch a webcast of this meeting, go to FDAAdvisoryCommittee.com]....
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.